The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
NHANES
elastography
fibroscan
hepatic steatosis
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
revised:
22
02
2024
received:
24
10
2023
accepted:
31
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
We investigated the current prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and fibrosis/cirrhosis and identified at-risk populations for MASLD and MASLD-related fibrosis among US adolescents and young adults in the United States. Utilizing the National Health and Nutrition Examination Survey 2017-2020, the prevalence of MASLD and fibrosis/cirrhosis was assessed via controlled attenuation parameter (CAP) score and liver stiffness measurements by transient elastography in participants aged 12-29 years with at least one cardiometabolic criteria and absence of other chronic liver disease. Multivariable logistic regression was performed to determine predictors of MASLD and MASLD-related fibrosis. The overall prevalence of MASLD was 23.9% (95% CI: 21.3-26.5 for CAP ≥ 263 dB/m) and 17.3% (95% CI: 14.7-20.0 for ≥285 dB/m), respectively. The prevalence of fibrosis and cirrhosis in MASLD was 11.0% and 3.1%, respectively. When categorized by age, the prevalence of MASLD varied from 16.8% (of which 6.2% [fibrosis], 1.8% [cirrhosis]) in early and middle adolescents (12-17 years), to 25.5% (11.8% [fibrosis], 4.8% [cirrhosis]) in late adolescents and young adults (18-24 years), and to 30.4% (of which 13.2% [fibrosis] and 2.1% [cirrhosis]) in older young adults (25-29 years). The independent predictors for MASLD included male sex, Hispanic, non-Hispanic Asian, body mass index, and low HDL-cholesterol. In contrast, diabetes and body mass index were associated with an increased risk of fibrosis in individuals with MASLD. The prevalence of MASLD and related fibrosis in adolescents and young adults in the United States has reached a significant level, with a substantial proportion of cirrhosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : None
Informations de copyright
© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Références
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966‐1986.
Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021;15(2):206‐216.
Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non‐alcoholic fatty liver disease and childhood obesity. Arch Dis Child. 2021;106(1):3‐8.
Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non‐alcoholic fatty liver disease in children and adolescents: a systematic review and meta‐analysis. PLoS One. 2015;10(10):e0140908.
Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007‐2016. Hepatol Commun. 2021;5(10):1676‐1688.
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57(4):1357‐1365.
Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction‐associated fatty liver disease is associated with increased all‐cause mortality in the United States. J Hepatol. 2021;75(6):1284‐1291.
Simon TG, Roelstraete B, Hartjes K, et al. Non‐alcoholic fatty liver disease in children and young adults is associated with increased long‐term mortality. J Hepatol. 2021;75(5):1034‐1041.
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319‐334.
Condon S, Hu H, Kong M, et al. ALT poorly predicts nonalcoholic fatty liver disease (NAFLD) and liver fibrosis as determined by vibration‐controlled transient elastography in adult national health and nutrition examination survey 2017‐2018: ALT poorly predicts NAFLD and hepatic fibrosis. Am J Med Sci. 2024;367(5):310‐322.
Castera L, Friedrich‐Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264‐1281.e4.
Johnson CL, Dohrmann SM, Burt VL, et al. National health and nutrition examination survey: sample design, 2011‐2014. Vital Health Stat 2. 2014;162:1‐33.
Kim D, Dennis BB, Cholankeril G, Ahmed A. Association between depression and metabolic dysfunction‐associated fatty liver disease/significant fibrosis. J Affect Disord. 2023;329:184‐191.
Kim D, Cholankeril G, Dennis BB, et al. Trends in the prevalence of hepatitis C virus infection based on the insurance status in the United States from 2013 to 2018. Liver Int. 2022;42(2):340‐349.
Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol. 2022;20(6):e1438‐e1455.
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration‐Controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156‐163.e2.
Petta S, Di Marco V, Pipitone RM, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int. 2018;38(11):2060‐2068.
Abeysekera KWM, Fernandes GS, Hammerton G, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population‐based study. Lancet Gastroenterol Hepatol. 2020;5(3):295‐305.
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717‐1730.
Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017‐2018. Clin Gastroenterol Hepatol. 2021;19(7):1499‐1501.e2.
Ciardullo S, Monti T, Perseghin G. Prevalence of liver steatosis and fibrosis detected by transient elastography in adolescents in the 2017‐2018 national health and nutrition examination survey. Clin Gastroenterol Hepatol. 2021;19(2):384‐390.e1.
Alkhouri N, Almomani A, Le P, et al. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. BMC Gastroenterol. 2022;22(1):366.
Mrad RA, Merjaneh N, Mubarak G, Lopez R, Zein NN, Alkhouri N. The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: a growing epidemic. Hepatology. 2016;64(4):1386‐1387.
Mann JP, Tang GY, Nobili V, Armstrong MJ. Evaluations of lifestyle, dietary, and pharmacologic treatments for pediatric nonalcoholic fatty liver disease: a systematic review. Clin Gastroenterol Hepatol. 2019;17(8):1457‐1476.e7.
Kim D, Perumpail BJ, Cholankeril G, Ahmed A. Association between food insecurity and metabolic dysfunction‐associated steatotic liver disease/significant fibrosis measured by fibroscan. Eur J Nutr. 2024;63:995‐1001.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516‐537.
Desai NK, Harney S, Raza R, et al. Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients. J Pediatr. 2016;173:160‐164.e1.